540501-56-2

Basic information

• Product Name: 1-Boc-2-hydroxyMethyl-4-M...
• Synonyms: 1-Boc-2-hydroxyMethyl-4-M...;1-Boc-2-hydroxyMethyl-4-Methylpyrrolidine;1-Pyrrolidinecarboxylicacid,2-(hydroxyMethyl)-4-Methyl-,1,1-diMethylethylester,(2S,4S)-;(2S,4S)-1-Boc-2-hydroxyMethyl-4-Methylpyrrolidine;tert-butyl (2S,4S)-2-(hydroxymethyl)-4-methylpyrrolidine-1-carboxylate;(2S,4S)-tert-Butyl 2-(hydroxymethyl)-4-methylpyrrolidine-1-carboxylate
• CAS NO: 540501-56-2
• Molecular Formula: C₁₁H₂₁NO₃
• Molecular Weight: 215.29
• Mol File: 540501-56-2.mol
• Article Data: 10

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 1-Boc-2-hydroxyMethyl-4-M...(CAS DataBase Reference)
• NIST Chemistry Reference: 1-Boc-2-hydroxyMethyl-4-M...(540501-56-2)
• EPA Substance Registry System: 1-Boc-2-hydroxyMethyl-4-M...(540501-56-2)

Safety Data

• Hazardous Substances Data: 540501-56-2(Hazardous Substances Data)

Usage

General Description

"1-Boc-2-hydroxyMethyl-4-M" refers to a class of chemical compounds that are often used in scientific research, specifically in the synthesis of other compounds. The "Boc" in its name refers to a tert-butyloxycarbonyl protective group, a common protection for amines in organic synthesis. The "hydroxyMethyl" suggests that this compound has alcohol functionality. The "4-M..." suggests the presence of a fourth substituent which is not fully specified. It's likely used in the production of pharmaceuticals, biochemicals and other organic compounds. However, without the full name of the compound, it's difficult to provide specifics about its properties or uses.

Upstream product

• 1560646-40-3 C₁₁H₁₉NO₃ 
• 364750-81-2 N-tert-Butyloxycarbonyl-(2S,4S)-4-methylproline 
• 125653-58-9 (2S,4R)-2-(tert-butyldimethylsilanyloxymethyl)-4-hydroxy-pyrrolidine-1-carboxylic acid tert-butyl ester 
• 13726-69-7 (2S,4R)-4-hydroxy-1-[(2-methylpropan-2-yl)oxycarbonyl]pyrrolidine-2-carboxylic acid 
• 61478-26-0 tert-butyl (2S,4R)-4-hydroxy-2-hydroxymethyl-pyrrolidine-1-carboxylate 
• 24424-99-5 di-tert-butyl dicarbonate 
• 540501-65-3 (S)-2-tert-butyldimethylsilyloxymethyl-N-tert-butyloxycarbonyl-4-(phenylthio)methylenepyrrolidine 
• 220993-22-6 (S)-tert-butyl 2-((tert-butyldimethylsilyloxy)methyl)-4-oxopyrrolidine-1-carboxylate 
• 51-35-4 4R-4-hydroxyproline 

Downstream Products

• 1560643-76-6 C₄₃H₅₄N₆O₄ 
• 1560639-00-0 C₄₇H₆₀N₈O₆ 
• 1283145-91-4 ((2S,4S)-1-(4-bromophenyl)-4-methylpyrrolidin-2-yl)methanol 
• 1283145-92-5 2-((2S,4S)-1-(4-bromophenyl)-4-methylpyrrolidin-2-yl)acetonitrile 
• 1283145-93-6 2-((2S,4S)-4-methyl-1-(4-(2-methylbenzyl)phenyl)pyrrolidin-2-yl)acetonitrile 
• 1283142-47-1 2-((2S,4S)-4-methyl-1-(4-(2-methylbenzyl)phenyl)pyrrolidin-2-yl)acetic acid trifluoroacetic acid salt 
• 364750-81-2 N-tert-Butyloxycarbonyl-(2S,4S)-4-methylproline 
• 901139-63-7 N-9-fuorenylmethoxycarbonyl-(2S,4R)-4-methylprolyl-(2S,4S)-4-methylprolyl-glycine benzyl ester 
• 901139-37-5 N-9-fuorenylmethoxycarbonyl-(2S)-prolyl-(2S,4S)-4-methylprolyl-glycine benzyl ester 
• 901139-29-5 N-tert-butyloxycarbonyl-(2S,4S)-4-methylprolyl-glycine benzyl ester 

Relevant articles and documents

Asymmetric hydrogenations for the synthesis of boc-protected 4-alkylprolinols and prolines

The utility of 4-substituted prolinols and their corresponding prolines in peptides, peptidomimetics, and natural products has motivated researchers to find new and efficient routes for their preparation. Herein, we report a general approach to the synthesis of Boc-protected 4-alkylprolinols and prolines via a divergent asymmetric hydrogenation strategy. Intermediate exocyclic olefins were prepared by Wittig-type reactions with ketone 6 and subjected to hydroxyl and sterically directed reductions. The Crabtree catalyst (Ir[COD] PyPCy3PF6) proved to be highly effective in diastereoselective hydrogenations to give trans- substituted pyrrolidines (9). Good facial selectivities were also observed in heterogeneous hydrogenations with Raney-nickel to obtain cis-substituted pyrrolidines (11). Employing this strategy, we describe the synthesis of novel prolinol and proline-based building blocks for incorporation into biologically relevant peptidomimetics.

Discovery of Pyrrolidine-Containing GPR40 Agonists: Stereochemistry Effects a Change in Binding Mode

A novel series of pyrrolidine-containing GPR40 agonists is described as a potential treatment for type 2 diabetes. The initial pyrrolidine hit was modified by moving the position of the carboxylic acid, a key pharmacophore for GPR40. Addition of a 4-cis-CF3 to the pyrrolidine improves the human GPR40 binding Ki and agonist efficacy. After further optimization, the discovery of a minor enantiomeric impurity with agonist activity led to the finding that enantiomers (R,R)-68 and (S,S)-68 have differential effects on the radioligand used for the binding assay, with (R,R)-68 potentiating the radioligand and (S,S)-68 displacing the radioligand. Compound (R,R)-68 activates both Gq-coupled intracellular Ca2+ flux and Gs-coupled cAMP accumulation. This signaling bias results in a dual mechanism of action for compound (R,R)-68, demonstrating glucose-dependent insulin and GLP-1 secretion in vitro. In vivo, compound (R,R)-68 significantly lowers plasma glucose levels in mice during an oral glucose challenge, encouraging further development of the series.

Bridged Ring compounds As Hepatitis C Virus (HCV) Inhibitors And Pharmaceutical Applications Thereof

Provided herein is a compound having Formula (I), or a stereoisomer, a geometric isomer, a tautomer, an N-oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, which can be used for treating HCV infection or a HCV disorder. Also provided herein are pharmaceutical compositions comprising the compounds disclosed herein, which can be used for treating HCV infection or a HCV disorder.